Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003401 · ClinicalTrials.gov registry record · Phase 2
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma
A Phase 2 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00003401: Completed Phase 2 study, sponsored by University of Maryland, Baltimore.
NCT00003401 is a Phase 2 study that has completed, run by University of Maryland, Baltimore. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003401, a Phase 2 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation plus combination chemotherapy in treating patients who have multiple myeloma that has been treated for longer than 12 months.
Interventions
- DRUG cisplatin
- DRUG cyclophosphamide
- DRUG dexamethasone
- DRUG etoposide
- DRUG carmustine
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-01 |
| Est. Completion | 2002-09 |
| Phase | Phase 2 |
What the finished NCT00003401 record still lists
NCT00003401 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00003401 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003401 about?
NCT00003401 is a clinical study titled "Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial...
What is the current status of trial NCT00003401?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-01. Estimated completion is 2002-09.
What interventions are being tested in trial NCT00003401?
The interventions under investigation include: cisplatin (DRUG), cyclophosphamide (DRUG), dexamethasone (DRUG), etoposide (DRUG), carmustine (DRUG).
Who is sponsoring clinical trial NCT00003401?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia